Geovax Labs Inc(GOVX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:54 PM ET (Korea 10/31 06:54)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -13.93 | Insider Own | 0.03% | Shs Outstand | 10.1M | Perf Week | -18.16% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 48.64% | Insider Trans | - | Shs Float | 10.1M | Perf Month | -47.67% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -1.09 | Inst Own | 4.89% | Short Float | 2.68% | Perf Quarter | -76.74% |
| Income | -0.02B | P/S | - | EPS this Y | 77.05% | Inst Trans | 5.57% | Short Ratio | 0.35 | Perf Half Y | -85.4% |
| Sales | 0.00B | P/B | 0.71 | EPS next 5Y | - | ROA | -408.8% | Short Interest | 0.27M | Perf YTD | -96.06% |
| Book/sh | 0.24 | P/C | 0.54 | EPS past 3/5Y | 58.34% 51.11% | ROE | -891.59% | 52W High | -98.84% ($14.50) | Perf Year | -98.8% |
| Cash/sh | 0.31 | P/FCF | - | Sales past 3/5Y | - 6.42% | ROIC | -1058.19% | 52W Low | -8.07% ($0.18) | Perf 3Y | -99.91% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 77.63% | Gross Margin | - | Volatility(W/M) | 10.18% 12.3% | Perf 5Y | -99.99% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.03 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 1.54 | EPS Q/Q | 88.91% | Profit Margin | - | RSI (14) | 17.16 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.54 | Sales Q/Q | -100% | SMA20 | -29.82% ($0.24) | Beta | 3.79 | Target Price | $10 |
| Payout | - | Debt/Eq | 0.18 | Earnings | 2026/08/12 | SMA50 | -55.56% ($0.38) | Rel Volume | 0.52 | Prev Close | $0.19 |
| Employees | 19 | LT Debt/Eq | 0.1 | EPS/Sales Surpr. | 19.17% - | SMA200 | -86.6% ($1.27) | Avg Volume(3M) | 0.76M | Price | $0.17 |
| IPO | 1997/5/12 | Option/Short | No/Yes | Trades | 448 | Volume | 394,100 | Change | -9.31% |
💉 Geovax Labs is a U.S. Nasdaq-listed clinical-stage biotech company developing vaccines and immunotherapies targeting infectious diseases and cancer. It has a multi-asset pipeline including GEO-CM04S1, a next-generation COVID-19 vaccine; GEO-MVA, a next-generation vaccine against mpox (monkeypox) and smallpox; and Gedeptin®, an anticancer gene therapy candidate.
Over the past 1 year, on the lower side
99% below its 1-year high.
Traded less than usual. That is 52% of its average volume.
GOVX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +77.0% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #584 of 597 in the industry
Based on market cap of $2M.
XRTX#582 XORTX Therapeutics Inc $2M PER - 
KAPA#583 Kairos Pharma Ltd $2M PER - GOVX#584 Geovax Labs Inc $2M PER - 
OGEN#585 Oragenics Inc $2M PER - 
VRAX#586 Virax Biolabs Group Ltd $2M PER - 
FAQ
What kind of company is GOVX?
GOVX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GOVX?
The market cap of GOVX is approximately $2M, ranking 5,823 within its sector.
What is the 52-week high and low for GOVX?
GOVX has recorded a 52-week high of $14.50 and a low of $0.18.
